On May 7th, Takeda Pharmaceutical Company Limited and Inviragen, Inc. jointly announced that they have entered into a definitive agreement for Takeda to acquire Inviragen, whose DENVax dengue vaccine candidate is currently being evaluated in dengue endemic areas.
A new study published in Nature online last week estimates that there are more than three times as many dengue infections as in the official World Health Organization (WHO) figure. The WHO estimates 50-100 million dengue infections a year, while “The global distribution and burden of dengue” report argues that...
On April 9-11, DVI, in collaboration with the Brazil Ministry of Health, convened a meeting in Brasilia, Brazil to bring together several developing countries likely to be among the first-to-introduce dengue vaccines. Major attention wasaccorded to identifying introduction strategies and to regulatory issues.
With the end of 2012 and the start of a new year, we wanted to take this opportunity to review the progress that has been made in heightening public awareness and political will around dengue vaccines, and in progress toward dengue vaccine development, including the first Phase 2 clinical trial results for a dengue vaccine candidate.
The Financial Times reports on dengue and the challenges of developing a dengue vaccine.
The Dengue Vaccine Initiative’s latest newsletter includes an update on dengue vaccines and discusses next steps in the development of a dengue vaccine.
Today, The Dengue Vaccine Initiative (DVI) welcomed new clinical trial results that reveal progress in developing the first-ever dengue vaccine. In a publication in The Lancet pharmaceutical company Sanofi Pasteur reported results from the first study conducted to evaluate the efficacy of any dengue vaccine candidate against clinical dengue disease in a population naturally exposed to dengue.
New study published in Vaccine indicates cost of production could be as low as $0.20 per dose.
Ministers of Health from 194 countries at the Sixty-fifth World Health Assembly today endorsed a landmark Global Vaccine Action Plan (GVAP), a roadmap to prevent millions of deaths by 2020 through more equitable access to existing vaccines for people in all communities.
Next week, the International Vaccine Access Center (IVAC) at Johns Hopkins University, in partnership with the Pan-American Health and Education Foundation (PAHEF), will gather experts from the Latin America and Caribbean regions in Baltimore, MD to develop guidelines and standards for costing dengue, in order to provide robust information on the true cost of dengue to local and regional-decision makers.